SCHEMBL24559153

SCHEMBL24559153

CN1C(=O)C(=Cc2ccc(Cn3cnc4c3c(=S)n(C)c(=O)n4C)cc2)C(=O)N(C)C1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ ADORA2B P29275 5/20 0.49
▸ SMN1; SMN2 Q16637 4/20 0.49
▸ RXFP1 Q9HBX9 3/20 0.49
▸ ABCC8 Q09428 1/20 0.49
▸ KCNJ11 Q14654 1/20 0.49
▸ HTT P42858 2/20 0.47
▸ UBE2N P61088 2/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ GLA P06280 1/20 0.44
▸ POLB P06746 1/20 0.43
▸ HIF1A Q16665 1/20 0.43
▸ TP53 P04637 1/20 0.41
▸ MAPT P10636 4/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA7 P43166 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24559158 0.90 LMNA (0.64) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1
SCHEMBL24559156 0.85 LMNA (0.49) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1
SCHEMBL24666143 0.85 LMNA (0.58) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1
SCHEMBL24559129 0.82 LMNA (0.60) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1
SCHEMBL24559151 0.81 LMNA (0.48) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1
SCHEMBL22521806 0.79 SMN1; SMN2 (0.76) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1
SCHEMBL24559279 0.79 MYC (0.52) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1
SCHEMBL24559245 0.77 LMNA (0.60) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1
SCHEMBL24666144 0.76 LMNA (0.46) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1
SCHEMBL24559355 0.76 LMNA (0.55) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220202821-A1 SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-06-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220202821-A1 SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF PARG, PARP15, PLG LMNA 854/4885MAPK1 2790/4885ADORA2B 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback